Please join us at this symposium, in a commitment to quality for the benefit of patients and consumers. A part of the SBIA Regulatory Education for Industry (REdI) series, the symposium will address the latest developments in pharmaceutical quality and highlight ways in which innovations have been embraced in a changing world. Speakers will:
Share lessons learned from the COVID-19 public health emergency.
Describe recent regulatory innovations related to pharmaceutical quality.
Connect science and research to regulatory actions.
Explain how the FDA is supporting the use of new technologies in the manufacture of pharmaceuticals.
TOPICS COVERED
Learning From the COVID-19 Public Health Emergency, including a panel discussion of FDA leaders
Innovations at FDA
A Foundation of Science
Advancing Advanced Manufacturing
KEYNOTE SPEAKER
Janet Woodcock M.D. Acting Commissioner Food and Drugs Food and Drug Administration
INTENDED AUDIENCE
Healthcare professionals interested in the FDA's work on pharmaceutical quality.
Manufacturing professionals
Regulatory affairs professionals
Foreign regulators
CONTINUING EDUCATION
Real-time attendance is required for the certificate of attendance which can be used in support of CEs for the following professional organizations. Certificates are only available during the two weeks post-event.
This course has been:
pre-approved by RAPS as eligible for a maximum of 12 credits for a two day event (appropriate to real-time attendance) towards a participant's RAC recertification upon full completion.
pre-approved by SOCRA who accepts documentation of candidate participation in continuing education programs for re-certification if the program is applicable to clinical research regulations, operations or management, or to the candidate's clinical research therapeutic area.
pre-approved by SQA as eligible for 1 non-GCP or non-GLP unit for every 1 hour of instructional time towards a participant's RQAP re-registration.
approved by ACRP for continuing education in clinical research. ACRP will provide 1 ACRP contact hour for every 45-60 minutes of qualified material.
The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research provides guidance, education and updates for regulated industry.
This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 10903 New Hampshire Ave · Silver Spring, MD · 20993-0002 · 1-888-INFO-FDA
No comments:
Post a Comment